Paclitaxel Docosahexaenoic Acid

Summary

Paclitaxel Docosahexaenoic Acid (CHEMBL4297441) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including non-small cell lung carcinoma and hepatocellular carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 9
• Chemistry: 1164.4 Da · C69H81NO15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297441
Name	Paclitaxel Docosahexaenoic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918473
Molecular formula	C69H81NO15
Molecular weight	1164.4
InChIKey	LRCZQSDQZJBHAF-PUBGEWHCSA-N

SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H]([C@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2)C(=O)O[C@H]3C[C@]4([C@H]([C@H]5[C@@]([C@H](C[C@@H]6[C@]5(CO6)OC(=O)C)O)(C(=O)[C@@H](C(=C3C)C4(C)C)OC(=O)C)C)OC(=O)C7=CC=CC=C7)O

IUPAC name: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

Also known as: Dha paclitaxel, Dha-paclitaxel, Paclitaxel docosahexaenoic acid, Paclitaxel-dha, Taxoprexin, PACLITAXEL DOCOSAHEXAENOIC ACID

Patent coverage: 506 distinct patent families (1,139 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
metastatic melanoma	2	MONDO:0005191	EFO:0002617

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00087776	PHASE3	TERMINATED	Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
NCT00243867	PHASE3	COMPLETED	Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
NCT00024375	PHASE2	UNKNOWN	DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
NCT00024388	PHASE2	UNKNOWN	Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00024401	PHASE2	UNKNOWN	DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
NCT00024414	PHASE2	UNKNOWN	DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
NCT00244816	PHASE2	COMPLETED	Taxoprexin® Treatment for Advanced Eye Melanoma
NCT00249262	PHASE2	COMPLETED	Taxoprexin Treatment for Advanced Skin Melanoma
NCT00422877	PHASE2	TERMINATED	Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).